BACKGROUND: Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone implicated in disorders of serum phosphorus concentration and vitamin D. The role of FGF23 in vascular calcification remains controversial. METHODS: Relationships between FGF23 and coronary artery calcified atherosclerotic plaque (CAC), aortoiliac calcified plaque (CP), carotid artery CP, volumetric bone mineral density (vBMD), albuminuria, and estimated glomerular filtration rate (eGFR) were determined in 545 African Americans with type 2 diabetes (T2D) and preserved kidney function in African American-Diabetes Heart Study participants. Generalized linear models were fitted to test associations between FGF23 and cardiovascular, bone, and renal phenotypes, and change in measurements over time, adjusting for age, gender, African ancestry proportion, body mass index, diabetes duration, hemoglobin A1c, blood pressure, renin-angiotensin-system inhibitors, statins, calcium supplements, serum calcium, and serum phosphate. RESULTS: The sample was 56.7% female with a mean (SD) age of 55.6 (9.6) years, diabetes duration of 10.3 (8.2) years, eGFR 90.9 (22.1) ml/min/1.73 m2, urine albumin:creatinine ratio (UACR) 151 (588) (median 13) mg/g, plasma FGF23 161 (157) RU/ml, and CAC 637 (1,179) mg. In fully adjusted models, FGF23 was negatively associated with eGFR (p < 0.0001) and positively associated with UACR (p < 0.0001) and CAC (p = 0.0006), but not with carotid CP or aortic CP. Baseline FGF23 concentration did not associate with changes in vBMD or CAC after a mean of 5.1 years follow-up. CONCLUSIONS: Plasma FGF23 concentrations were independently associated with subclinical coronary artery disease, albuminuria, and kidney function in the understudied African American population with T2D. Findings support relationships between FGF23 and vascular calcification, but not between FGF23 and bone mineral density, in African Americans lacking advanced nephropathy.
BACKGROUND:Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone implicated in disorders of serum phosphorus concentration and vitamin D. The role of FGF23 in vascular calcification remains controversial. METHODS: Relationships between FGF23 and coronary artery calcified atherosclerotic plaque (CAC), aortoiliac calcified plaque (CP), carotid artery CP, volumetric bone mineral density (vBMD), albuminuria, and estimated glomerular filtration rate (eGFR) were determined in 545 African Americans with type 2 diabetes (T2D) and preserved kidney function in African American-Diabetes Heart Study participants. Generalized linear models were fitted to test associations between FGF23 and cardiovascular, bone, and renal phenotypes, and change in measurements over time, adjusting for age, gender, African ancestry proportion, body mass index, diabetes duration, hemoglobin A1c, blood pressure, renin-angiotensin-system inhibitors, statins, calcium supplements, serum calcium, and serum phosphate. RESULTS: The sample was 56.7% female with a mean (SD) age of 55.6 (9.6) years, diabetes duration of 10.3 (8.2) years, eGFR 90.9 (22.1) ml/min/1.73 m2, urine albumin:creatinine ratio (UACR) 151 (588) (median 13) mg/g, plasma FGF23 161 (157) RU/ml, and CAC 637 (1,179) mg. In fully adjusted models, FGF23 was negatively associated with eGFR (p < 0.0001) and positively associated with UACR (p < 0.0001) and CAC (p = 0.0006), but not with carotid CP or aortic CP. Baseline FGF23 concentration did not associate with changes in vBMD or CAC after a mean of 5.1 years follow-up. CONCLUSIONS: Plasma FGF23 concentrations were independently associated with subclinical coronary artery disease, albuminuria, and kidney function in the understudied African American population with T2D. Findings support relationships between FGF23 and vascular calcification, but not between FGF23 and bone mineral density, in African Americans lacking advanced nephropathy.
Authors: M Schoppet; L C Hofbauer; N Brinskelle-Schmal; A Varennes; J Goudable; M Richard; G Hawa; R Chapurlat; P Szulc Journal: J Clin Endocrinol Metab Date: 2012-02-08 Impact factor: 5.958
Authors: Natalie A van Venrooij; Renata C Pereira; Yin Tintut; Michael C Fishbein; Navdeep Tumber; Linda L Demer; Isidro B Salusky; Katherine Wesseling-Perry Journal: Nephrol Dial Transplant Date: 2014-01-23 Impact factor: 5.992
Authors: Jeffrey J Hsu; Ronit Katz; Joachim H Ix; Ian H de Boer; Bryan Kestenbaum; Michael G Shlipak Journal: Nephrol Dial Transplant Date: 2014-04-29 Impact factor: 5.992
Authors: Yifu Fang; Charles Ginsberg; Michael Seifert; Olga Agapova; Toshifumi Sugatani; Thomas C Register; Barry I Freedman; Marie-Claude Monier-Faugere; Hartmut Malluche; Keith A Hruska Journal: J Am Soc Nephrol Date: 2014-02-27 Impact factor: 10.121
Authors: Neerupma Silswal; Chad D Touchberry; Dorothy R Daniel; Darla L McCarthy; Shiqin Zhang; Jon Andresen; Jason R Stubbs; Michael J Wacker Journal: Am J Physiol Endocrinol Metab Date: 2014-07-22 Impact factor: 4.310
Authors: Vincent M Brandenburg; Marcus E Kleber; Marc G Vervloet; Andreas Tomaschitz; Stefan Pilz; Tatjana Stojakovic; Graciela Delgado; Tanja B Grammer; Nikolaus Marx; Winfried März; Hubert Scharnagl Journal: Atherosclerosis Date: 2014-08-28 Impact factor: 5.162
Authors: Olena Andrukhova; Svetlana Slavic; Alina Smorodchenko; Ute Zeitz; Victoria Shalhoub; Beate Lanske; Elena E Pohl; Reinhold G Erben Journal: EMBO Mol Med Date: 2014-04-06 Impact factor: 12.137
Authors: Kazuyuki Yahagi; Frank D Kolodgie; Christoph Lutter; Hiroyoshi Mori; Maria E Romero; Aloke V Finn; Renu Virmani Journal: Arterioscler Thromb Vasc Biol Date: 2016-12-01 Impact factor: 8.311
Authors: Sibel Gulcicek; Carmine Zoccali; Deniz Çebi Olgun; Giovanni Tripepi; Selma Alagoz; Serkan Feyyaz Yalın; Sinan Trabulus; Mehmet R Altiparmak; Nurhan Seyahi Journal: Cardiorenal Med Date: 2017-07-13 Impact factor: 2.041
Authors: Gary C Chan; Jasmin Divers; Gregory B Russell; Carl D Langefeld; Lynne E Wagenknecht; Fang-Chi Hsu; Jianzhao Xu; S Carrie Smith; Nicholette D Palmer; Pamela J Hicks; Donald W Bowden; Thomas C Register; Lijun Ma; J Jeffrey Carr; Barry I Freedman Journal: Diabetes Care Date: 2017-11-07 Impact factor: 19.112
Authors: Salim S Hayek; Jasmin Divers; Mohamad Raad; Jianzhao Xu; Donald W Bowden; Melissa Tracy; Jochen Reiser; Barry I Freedman Journal: J Am Heart Assoc Date: 2018-05-01 Impact factor: 5.501